drugset
drugset / Trial / NCT01675791

A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet

NCT01675791 ↗

Phase 2 Completed 637 enrolled ALK-Abelló A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary aim of this trial is to evaluate the dose-response relationship for the ALK tree AIT administered once daily in order to define a dose-range that would be suitable for at-home administration.

Timeline

Start
2012-08
Primary completion
2013-07
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ALK tree AIT Unknown 0.5 unknown Other
Subject ALK tree AIT Unknown 1 unknown Other
Subject ALK tree AIT Unknown 2 unknown Other
Subject ALK tree AIT Unknown 4 unknown Other
Subject ALK tree AIT Unknown 7 unknown Other
Subject ALK tree AIT Unknown 12 unknown Other

Indications

No indication recorded.